Last reviewed · How we verify
GEN-725 tablets
At a glance
| Generic name | GEN-725 tablets |
|---|---|
| Sponsor | Henan Genuine Biotech Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib (PHASE1, PHASE2)
- A Phase Ⅰ Clinical Study of GEN-725 Tablets in Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GEN-725 tablets CI brief — competitive landscape report
- GEN-725 tablets updates RSS · CI watch RSS
- Henan Genuine Biotech Co., Ltd. portfolio CI